Zacks Research Has Positive Opinion of RDY FY2027 Earnings

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Investment analysts at Zacks Research increased their FY2027 earnings per share estimates for Dr. Reddy’s Laboratories in a research note issued on Friday, November 6th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.44 for the year, up from their previous estimate of $0.43. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.46 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2027 earnings at $0.10 EPS, Q3 2028 earnings at $0.15 EPS, Q4 2028 earnings at $0.14 EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $0.65 EPS.

Several other research firms have also recently issued reports on RDY. Jefferies Financial Group upgraded shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “hold” rating and set a $13.90 target price for the company in a research note on Sunday, October 25th. JPMorgan Chase & Co. upgraded shares of Dr. Reddy’s Laboratories from an “underweight” rating to a “neutral” rating in a research report on Monday, October 26th. Citigroup raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and lifted their price objective for the company from $1,040.00 to $1,450.00 in a report on Tuesday, September 29th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Dr. Reddy’s Laboratories in a research report on Wednesday, October 21st. Finally, Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, October 17th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $492.90.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $14.88 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.93 and a quick ratio of 1.40. The stock has a market capitalization of $12.42 billion, a price-to-earnings ratio of 40.20, a PEG ratio of 3.12 and a beta of 0.31. The firm’s 50 day simple moving average is $12.88 and its 200-day simple moving average is $13.27. Dr. Reddy’s Laboratories has a 12 month low of $11.36 and a 12 month high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Saturday, October 24th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. Dr. Reddy’s Laboratories had a return on equity of 7.91% and a net margin of 8.56%. The company had revenue of $903.89 million during the quarter, compared to the consensus estimate of $894.94 million.

Institutional Trading of Dr. Reddy’s Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the business. Ieq Capital LLC raised its stake in shares of Dr. Reddy’s Laboratories by 12.2% during the 3rd quarter. Ieq Capital LLC now owns 119,016 shares of the company’s stock worth $1,502,000 after buying an additional 12,918 shares during the period. Composition Wealth LLC acquired a new stake in Dr. Reddy’s Laboratories in the 3rd quarter valued at $241,000. Diversified Trust Co acquired a new stake in Dr. Reddy’s Laboratories in the 3rd quarter valued at $132,000. Allworth Financial LP increased its holdings in Dr. Reddy’s Laboratories by 34.1% in the 3rd quarter. Allworth Financial LP now owns 10,809 shares of the company’s stock worth $136,000 after acquiring an additional 2,747 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Dr. Reddy’s Laboratories by 1,150.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 80,500 shares of the company’s stock worth $1,016,000 after acquiring an additional 74,063 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.